Bluebird bio holds broad appeal for cancer-focused investors by virtue of its proprietary class of gene therapy drugs and an immunotherapy platform that is being developed through a joint venture with Celgene.
Treatments for leukaemia (and other forms of cancers) have long eluded the scientific community. An emerging class of companies, however, hold the potential to revolutionise patient care through targeted solutions, a sharp contrast to the indiscriminate approaches of chemotherapy.
Cancer therapeutics are a darling of the financial markets. The allure was evidenced by a series of capital raisings following presentations at the annual American Society of Hematologists convention held last week in San Francisco.